paperKB
coga / coga-kb
Help
Sign in

Chunk #61 — Pharmacokinetics of nicotine — CYP2A6

Source
Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.
Embedded
yes

Text

Several reduced and null activity alleles of the CYP2A6 gene have been identified and shown to alter enzyme activity and in vivo nicotine metabolism (Fernandez-Salguero et al. 1995; Goodz and Tyndale 2002; Mwenifumbo et al. 2008; Mwenifumbo and Tyndale 2007). The CYP2A6*1 allele is the “normal” activity (wild-type) variant and CYP2A6*1B is an increased activity allele (faster nicotine clearance). The CYP2A6*2 and *4 alleles are null activity alleles, occurring in about 20% of Asians and 1% of Caucasians (Nakajama et al. 2006; Rao et al. 2000; Schoedel et al. 2004). The CYP2A6*9 and *12 are found more commonly in Caucasian populations, about 9% of Caucasians carry one or more of these alleles (Malaiyandi et al. 2005; Schoedel et al. 2004). These alleles have reduced activity (slower nicotine clearance) (Mwenifumbo et al. 2008; Mwenifumbo and Tyndale 2007; Ray et al. 2009).